glp-1 shortage over The FDA says the is over, but a supply cliff is coming for compounded users. Read the report: https://glp-1.reviews/2026-global-glp-1-industry-statistics-the-definitive-data-report-on-pricing-supply-and-provider-integrity/?utm_source=instagram GLP-1 Shortage = Over -

such cases need to be carefully examined

[14] [15] Under NHS criteria, Saxenda is typically prescribed through specialist weight management services for adults who have a BMI of at least 35 kg/m (or at least 32.5 kg/m for certain ethnic groups) with prediabetes or type 2 diabetes, hypertension, dyslipidaemia or obstructive sleep apnoea, and have a high risk of cardiovascular disease

Optimize cost & market positioning: Cover both high-end and grassroots markets via process optimization and biosimilar development

Patients begin therapy with their first month's payment and continue with simple monthly renewalsno surprise billing, no hidden pharmacy fees, and no prior authorization delays

,